|
63
|
172
|
6ywkA |
Crystal structure of sars-cov-2 (covid-19) nsp3 macrodomain in complex with hepes |
|
79
|
304
|
6yz6A |
Structure of the hemiacetal complex between the sars-cov-2 main protease and leupeptin |
|
64
|
172
|
6ywmA |
Crystal structure of sars-cov-2 (covid-19) nsp3 macrodomain in complex with mes |
|
69
|
309
|
6yvaA |
Plpro-c111s with misg15 |
|
84
|
306
|
6yt8A |
Structure of sars-cov-2 main protease bound to pyrithione zinc |
|
79
|
306
|
6yvfA |
Structure of sars-cov-2 main protease bound to azd6482. |
|
116
|
636
|
6xty5 |
Cryoem structure of human cmg bound to and-1 (cmga) |
|
116
|
648
|
6xty6 |
Cryoem structure of human cmg bound to and-1 (cmga) |
|
106
|
613
|
6xty4 |
Cryoem structure of human cmg bound to and-1 (cmga) |
|
114
|
704
|
6xtx3 |
Cryoem structure of human cmg bound to atpgammas and dna |
|
127
|
774
|
6xtx6 |
Cryoem structure of human cmg bound to atpgammas and dna |
|
103
|
650
|
6xty2 |
Cryoem structure of human cmg bound to and-1 (cmga) |
|
117
|
636
|
6xtx5 |
Cryoem structure of human cmg bound to atpgammas and dna |
|
114
|
641
|
6xtx7 |
Cryoem structure of human cmg bound to atpgammas and dna |
|
120
|
641
|
6xty7 |
Cryoem structure of human cmg bound to and-1 (cmga) |
|
113
|
704
|
6xty3 |
Cryoem structure of human cmg bound to and-1 (cmga) |
|
110
|
613
|
6xtx4 |
Cryoem structure of human cmg bound to atpgammas and dna |
|
30
|
115
|
6xkmB |
Room temperature structure of sars-cov-2 nsp10/nsp16 methyltransferase in a complex with sam determined by fixed-target serial crystallography |
|
113
|
730
|
6xtx2 |
Cryoem structure of human cmg bound to atpgammas and dna |
|
85
|
302
|
6xhmA |
Covalent complex of sars-cov-2 main protease with n-[(2s)-1-({(2s,3s)-3,4-dihydroxy-1-[(3s)-2-oxopyrrolidin-3-yl]butan-2-yl}amino)-4-methyl-1-oxopentan-2-yl]-4-methoxy-1h-indole-2-carboxamide |
|
90
|
306
|
6xquA |
Extreme malleability of the sars-cov-2 3cl mpro active site cavity facilitates binding of clinical antivirals: prospects for repurposing existing drugs and ramifications for inhibitor design |
|
84
|
306
|
6xkfA |
The crystal structure of 3cl mainpro of sars-cov-2 with oxidized cys145 (sulfenic acid cysteine). |
|
89
|
306
|
6xoaA |
The crystal structure of 3cl mainpro of sars-cov-2 with c145s mutation |
|
91
|
313
|
6xg3A |
The crystal structure of papain-like protease of sars cov-2 , c111s mutant, at room temperature |
|
94
|
298
|
6xkmA |
Room temperature structure of sars-cov-2 nsp10/nsp16 methyltransferase in a complex with sam determined by fixed-target serial crystallography |
|
86
|
298
|
6xmkA |
1.70 a resolution structure of sars-cov-2 3cl protease in complex with inhibitor 7j |
|
82
|
306
|
6xqsA |
Extreme malleability of the sars-cov-2 3cl mpro active site cavity facilitates binding of clinical antivirals: prospects for repurposing existing drugs and ramifications for inhibitor design |
|
86
|
306
|
6xhuA |
Room temperature x-ray crystallography reveals oxidation and reactivity of cysteine residues in sars-cov-2 3cl mpro: insights for enzyme mechanism and drug design |
|
28
|
72
|
6xipA |
The 1.5 a crystal structure of the co-factor complex of nsp7 and the c-terminal domain of nsp8 from sars cov-2 |
|
75
|
306
|
6xqtA |
Extreme malleability of the sars-cov-2 3cl mpro active site cavity facilitates binding of clinical antivirals: prospects for repurposing existing drugs and ramifications for inhibitor design |
|
87
|
306
|
6xkhA |
The 1.28a crystal structure of 3cl mainpro of sars-cov-2 with oxidized c145 (sulfinic acid cysteine) |
|
31
|
115
|
6xipB |
The 1.5 a crystal structure of the co-factor complex of nsp7 and the c-terminal domain of nsp8 from sars cov-2 |
|
85
|
306
|
6xchA |
Structure of the complex between the sars-cov-2 main protease and leupeptin |
|
82
|
307
|
6xbiA |
Crystal structure of the sars-cov-2 (covid-19) main protease in complex with inhibitor uaw248 |
|
85
|
306
|
6xb2A |
Room temperature x-ray crystallography reveals catalytic cysteine in the sars-cov-2 3cl mpro is highly reactive: insights for enzyme mechanism and drug design |
|
87
|
300
|
6xbgA |
Crystal structure of the sars-cov-2 (covid-19) main protease in complex with inhibitor uaw246 |
|
87
|
304
|
6xfnA |
Crystal structure of the sars-cov-2 (covid-19) main protease in complex with uaw243 |
|
89
|
347
|
6xdhA |
Crystal structure of nendou (uridylate-specific endoribonuclease, nsp15) from betacoronavirus sars-cov-2 |
|
87
|
304
|
6xbhA |
Crystal structure of the sars-cov-2 (covid-19) main protease in complex with inhibitor uaw247 |
|
92
|
306
|
6xb0A |
Room temperature x-ray crystallography reveals catalytic cysteine in the sars-cov-2 3cl mpro is highly reactive: insights for enzyme mechanism and drug design |
|
88
|
304
|
6xa4A |
Crystal structure of the sars-cov-2 (covid-19) main protease in complex with uaw241 |
|
87
|
309
|
6xaaA |
Sars cov-2 plpro in complex with ubiquitin propargylamide |
|
94
|
313
|
6xa9A |
Sars cov-2 plpro in complex with isg15 c-terminal domain propargylamide |
|
88
|
306
|
6xb1A |
Room temperature x-ray crystallography reveals catalytic cysteine in the sars-cov-2 3cl mpro is highly reactive: insights for enzyme mechanism and drug design |
|
89
|
348
|
6x4iA |
Crystal structure of nsp15 endoribonuclease from sars cov-2 in the complex with 3'-uridinemonophosphate |
|
95
|
320
|
6wx4D |
Crystal structure of the sars cov-2 papain-like protease in complex with peptide inhibitor vir251 |
|
88
|
348
|
6wxcA |
Crystal structure of nsp15 endoribonuclease from sars cov-2 in the complex with potential repurposing drug tipiracil |
|
95
|
315
|
6wzuA |
The crystal structure of papain-like protease of sars cov-2 , p3221 space group |
|
85
|
348
|
6x1bA |
Crystal structure of nsp15 endoribonuclease from sars cov-2 in the complex with the product nucleotide gpu. |
|
23
|
113
|
6wxdA |
Sars-cov-2 nsp9 rna-replicase |
